Pharmaceutical sponsors are fundamentally restructuring Phase III clinical trial design by shifting toward decentralized methodologies supported by medical-grade wearable sensors. The transition addresses chronic trial inefficiencies, including high participant attrition and delayed patient recruitment.
Data Integrity and Patient Retention
Continuous real-world data collection reduces reliance on periodic clinical visits, capturing transient adverse events that traditional monitoring frequently misses. Analytical data demonstrates decentralized trial frameworks reduce overall Phase III completion timelines by an average of four months while improving demographic diversity among trial cohorts.